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Fabrizio Montecucco, MD, PHD,a,b Federico Carbone, MD, PHDa,cP eople used to binging alcohol drinking or/andsmoking marijuana to enjoy the weekend arelikely not aware of their increased risk of
developing acute cardiovascular (CV) dysfunction,
cardiac arrhythmias, and other life-threatening con-
ditions affecting the liver and brain (1). In their
study in this issue of JACC: Basic to Translational
Science, Paloczi et al. (2) described how exaggerated
alcohol assumption, even in a single shot, may induce
severe CV dysfunction in mice.SEE PAGE 625It is noteworthy that the authors recognized the
up-regulation of the endogenous cannabinoid (also
referred to as endocannabinoid) anandamide as a
leading mechanism underlying alcohol-induced CV
dysfunction (3). Such results strongly suggest how the
concomitant assumption of alcohol and cannabinoids
may synergistically determine CV dysfunction.
Although those observations raise a warning for
public health, especially involving young people,
any translation to human beings still remainsISSN 2452-302X
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Our recommendation is justified by the following
reasons already acknowledged by the authors in their
article:
1) The study might suggest that both alcohol- and
cannabinoid-mediated effects on CV dysfunction
might trigger common pathways. Such evidence is
limited to the animal model, whereas further
data are needed to confirm a relevance for human
beings. Indeed,mouse and human pathophysiology
show several differences, especially concerning
metabolism and the toxicity of exogenous com-
pounds. Therefore, it often happens that intriguing
evidence in mice is no longer confirmed in humans.
2) The mouse model might be distant from real life
of human beings. Ethylic alcohol concentration
may be correctly estimated in mice but not in
humans. Indeed, wine, beer, and other alcoholic
beverages combine ethylic alcohol with other
“cardioprotective” compounds, such as poly-
phenols (3). Especially concerning moderate
assumption of red wine, several studies in past
decades investigated its antioxidant properties,
which may partially balance alcohol toxicity.
We need studies investigating whether this
so-called “French paradox” might have a role in
limiting the negative acute effects of binge alcohol
drinking (3).
3) Concomitant administration of exogenous canna-
binoids together with alcohol was not explored.
Therefore, we cannot conclude about a potential
synergistic toxicity of alcohol and cannabinoids
on cardiac function.
4) Additional mechanisms, such as increased
inflammation (elevated levels of macrophage
migration inhibitory factor [MIF], interleukin 1b,https://doi.org/10.1016/j.jacbts.2019.08.001
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639and interleukin-6), autophagy, and overt cardiac
apoptosis, potentially impacting acute
CV dysfunction were only partially explored,
suggesting that further studies are needed to
better clarify the relationship of alcohol and
endocannabinoids on CV dysfunction.
Therefore, much remains to discover and clarify.
Certainly, the authors might have identified an addi-
tional negative effect of excessive alcohol consump-
tion that should further discourage people to abuse. In
line with this, not only chronic alcohol abuse but also
acute alcohol intoxication would have a detrimental
role in triggering devastating complications (4).
Another strength of this study is the demonstration
that alcohol-induced cardiac dysfunction is depen-
dent on cannabinoid type 1 receptor (CB1) activation.
Being ubiquitously expressed in several tissues
(including brain, heart, vascular, and inflammatory
cells), CB1 has been extensively studied in the last
decade. Its activation has been associated with organ
dysfunction in different CV disease models. A specific
CB1 antagonist rimonabant was also proved to effec-
tively reduce body weight and CV risk in humans
in clinical trials, but the high rate of severe psychi-
atric adverse effects imposed withdrawal from the
market (4).
The results provided by Paloczi et al. are in line
with previous evidence indicating a pathophysiolog-
ical role of CB1 in CV injury. This is an intriguing issue
because beneficial effects of CB1 inhibition and/orCB2 activation were already demonstrated in other
CV disease models, including atherosclerosis and
related life-threatening complications (5). Ultimately,
this study should stimulate further efforts in devel-
oping new CB1 pharmacological antagonists that
do not pass the blood-brain barrier and therefore
are better tolerated. Because CB2 was recently
demonstrated to have anti-inflammatory activities
circulating inflammatory cells, it would be of partic-
ular interest to develop compounds that simulta-
neously inhibit CB1 and activate CB2 at the same
time (5).
Finally, we would stress future perspectives for
endocannabinoids and their transmembrane re-
ceptors in CV research. The authors involved in this
study are recognized as experts in this field of
research and some of them (i.e., Pal Pacher, George
Kunos, and Thomas Schindler) recently paved the
way for analyzing the cannabinoid system by using
cannabinoid tracers for cardiac nuclear imaging.
We believe that this exciting route would be a very
successful approach for translating mouse discoveries
in human beings and for performing therapeutic
strategies to limit alcohol-induced CV toxicity.
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